Evolving trends in lung cancer: Epidemiology, diagnosis, and management
Ramakant Deshpand, Manish Chandra, Amit RauthanIndian Journal of Cancer 2022 59(5):90-105
Lung cancer is one of the deadliest cancers globally and accounts for most of the cancer-related deaths in India. Comprehensive data on lung cancer in India are lacking. This review aimed to discuss the epidemiological trends of lung cancers and driver mutations as well as the recent advancements in molecular diagnostics and therapeutic options primarily in non–small cell lung cancer (NSCLC) in India. Electronic databases, such as PubMed and Google Scholar, were searched to retrieve the relevant literature published in t...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Ramakant Deshpand Manish Chandra Amit Rauthan Source Type: research
Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non & #8211;Small-Cell Lung Cancer
Meenu Walia, Manish K Singhal, Mangesh S KamleIndian Journal of Cancer 2022 59(5):80-89
Evidence from several studies has shown improved progression-free survival (PFS) with first- or second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) compared with chemotherapy for advanced NSCLC patients. But resistance to first or second-generation TKI therapies after 9 to 12 months of treatment initiation is a concern. Osimertinib is a third-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits both EGFRm (epidermal growth factor receptor mutated) and EGFR T...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Meenu Walia Manish K Singhal Mangesh S Kamle Source Type: research
Role of immunotherapy in metastatic EGFRm NSCLC: Is it relevant ?
Boman Dhabhar, Tarini P Sahoo, JK AkshayIndian Journal of Cancer 2022 59(5):68-79
EGFR-TKIs have changed the landscape of metastatic NSCLC treatment with a significant improvement in survival of EGFRm patients compared to wild-type EGFR. Even with the newer third generation EGFR TKIs like, Osimertinib, which has proven efficacy against the resistance mutation of EGFRm T790M, progression eventually occurs. There are limited treatment options for patients with metastatic EGFRm NSCLC with other acquired resistance. Therefore, novel therapeutic combination strategies are being researched to overcome potential resistance to EG...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Boman Dhabhar Tarini P Sahoo JK Akshay Source Type: research
BRCA mutations: Implications of genetic testing in ovarian cancer
Vineet Talwar, Amit RauthanIndian Journal of Cancer 2022 59(5):56-67
Ovarian cancer (OC) is one of the most lethal gynecological cancers with a 5-year survival rate that ranges from 30% to 40%. Breast cancer genes (BRCA1 and BRCA2) play a key role in maintaining genomic stability. Mutations in BRCA1/2 genes lead to the accumulation of double-strand breaks, resulting in tumorigenesis. The risk of developing OC in women with BRCA1 and BRCA2 mutations is 39% and 11%, respectively, by 70 years of age. BRCA1/2 mutation testing is thus important to identify women at greatest risk of d...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Vineet Talwar Amit Rauthan Source Type: research
Relevance of multi-disciplinary team approach in diagnosis and management of Stage III NSCLC
Ullas Batra, Anusheel Munshi, Vedant Kabra, Gagandeep MomiIndian Journal of Cancer 2022 59(5):46-55
Lung cancer is reported as the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) constitutes 80%–85% of all lung cancers. Diagnosis of NSCLC is a complex multistep process. The prognosis of NSCLC is poor as most of the patients are presented at the metastatic stage. The management of these patients needs the expertise of different specialists. A multidisciplinary team (MDT) comprising specialists from different disciplines has a substantial role in imp...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Ullas Batra Anusheel Munshi Vedant Kabra Gagandeep Momi Source Type: research
Expert survey on management of prostate cancer in India: Real-world insights into practice patterns
Ganesh Bakshi, Hemant Tongaonkar, Sanjai Addla, Santosh Menon, Aditya Pradhan, Abhay Kumar, Abhijit Bapat, Adwaita Gore, Amit Joshi, Anand Raja, Anil Bradoo, Anita Ramesh, Anup Kumar, Archi Agrawal, Asawari Ambekar, Ashish Joshi, Ashish Singh, Bhupendra Pal Singh, Deepak Dabkara, Dhiraj Khadakban, Gagan Gautam, Gagan Prakash, Harvinder Singh Pahwa, Hemant Kumar Goel, Jagdeesh Kulkarni, Jeeban Jyoti Mishra, Kaushal Patel, Mahendra Pal, Percy Jal Chibber, Priya Tiwari, Radheshyam Naik, SK Raghunath, Rahul Krishnatry, Rajendra Shimpi, Rakesh Sharma, Rakesh Taran, Sameer Trivedi, Sanjay Nabar, Sanjoy Surekha, Satish Kumar, Sat...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Ganesh Bakshi Hemant Tongaonkar Sanjai Addla Santosh Menon Aditya Pradhan Abhay Kumar Abhijit Bapat Adwaita Gore Amit Joshi Anand Raja Anil Bradoo Anita Ramesh Anup Kumar Archi Agrawal Asawari Ambekar Ashish Joshi Ashish Singh Bhupendra Pal Singh Deepak D Source Type: research
CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA & #42; versus tissue biopsy in patients with metastatic non-small cell lung cancer
Conclusions: This real-world study in Indian patients suggests that plasma testing for EGFR mutation analysis is a viable diagnostic option in newly diagnosed advanced/metastatic NSCLC patients. The noninvasive plasma procedure in patients without available/evaluable tumor sample may enable more patients to receive appropriate targeted therapies by providing clinicians with valuable insights into the patient's tumor mutation status.
ClinicalTrials.gov Identifier: NCT03562819 (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Kumar Prabhash Bivas Biswas Sachin Khurana Ullas Batra Ghanashyam Biswas Suresh Hariram Advani Prabrajya N Mohapatra Senthil Rajappa Ajay Sharma Shekhar Patil Palanki Satya Dattatreya Rakesh Roy Sachin Almel Gautam Goyal Narayanankutty Warrier Source Type: research
Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India
Conclusion: Our study confirms the favorable safety profile of osimertinib without any new safety concerns in Indian patients with EGFR T790M mutation-positive stage IV NSCLC.
ClinicalTrials.gov Identifier: NCT03853551
CTRI registration no. CTRI/2018/10/015941 (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Prabhat S Malik Vanita Noronha Deepak Dabkara Vamshi K Maddu Senthil Rajappa Sewanti Limaye Ullas Batra Source Type: research
Abstracts
Indian Journal of Cancer 2021 58(7):1-9 (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - February 4, 2022 Category: Cancer & Oncology Source Type: research
Oral presentation at the women & #39;s cancer initiative annual conference 2021
Indian Journal of Cancer 2021 58(6):1-16 (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - January 16, 2022 Category: Cancer & Oncology Source Type: research
Lessons from narrative medicine: Cancer care will improve with narrative oncology
Bidhu Kalyan MohantiIndian Journal of Cancer 2021 58(4):615-618
Narrative medicine (NM) is a new discipline in healthcare that helps the patients and physicians to tell and listen to the accounts of disease, illness, and suffering. In the last 20 years, NM has moved into the realms of biomedical education, research, and training. The complexity of cancer management can gain from the medical humanism of NM. A new model of cancer care called narrative oncology (NO) with NM-based skill sets of attention, representation, and affiliation can build narrative competence, therapeutic relationship, and clinical trust. The oncologi...
Source: Indian Journal of Cancer - December 31, 2021 Category: Cancer & Oncology Authors: Bidhu Kalyan Mohanti Source Type: research
News from the world of oncology
Indian Journal of Cancer 2021 58(4):635-637 (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - December 31, 2021 Category: Cancer & Oncology Source Type: research
Kaposiform hemangioendothelioma of leg: An unusual presentation
Adarsh W Barwad, Ekta Dhamija, Venkatesan S Kumar, Sameer Rastogi, Asit R MridhaIndian Journal of Cancer 2021 58(4):631-634 (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - December 31, 2021 Category: Cancer & Oncology Authors: Adarsh W Barwad Ekta Dhamija Venkatesan S Kumar Sameer Rastogi Asit R Mridha Source Type: research
Pediatric perivascular epithelioid cell tumor of the thigh: A great mimicker
Gnanapriya Vellaisamy, Anuradha Ananthamurthy, Kiran Mahadevappa, Suravi Mohanty, Kanishka DasIndian Journal of Cancer 2021 58(4):627-630 (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - December 31, 2021 Category: Cancer & Oncology Authors: Gnanapriya Vellaisamy Anuradha Ananthamurthy Kiran Mahadevappa Suravi Mohanty Kanishka Das Source Type: research
& #8220;Radiation recall phenomenon & #8221; in a patient with nasopharyngeal carcinoma: A unique presentation
Avik Mandal, Pritanjali Singh, Dharmendra SinghIndian Journal of Cancer 2021 58(4):625-626 (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - December 31, 2021 Category: Cancer & Oncology Authors: Avik Mandal Pritanjali Singh Dharmendra Singh Source Type: research
